AGX-392

N/A

Report date: 2026/04/17 10:36:25

Base Information

Drug NameAGX-392

Drug Alias NameSelected CD39+CD103+CD8+ ATC Gene ModifiedAGX-392

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacementsAnti-Ectonucleoside triphosphate diphosphohydrolase 1Cluster of differentiation 8 modulators

TargetsEctonucleoside triphosphate diphosphohydrolase 1Cluster of differentiation 8

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAgonOx Inc

China Registration ClassN/A

Develop Information

Active CompaniesAgonOx Inc

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A